The Fly | ABVX

Abivax SA Sponsored ADR

· ABVX

Dashboard

Financials

Ratios

Transcripts

Valuation

Over a week ago

Spyre Therapeutics price target raised by $13 at Deutsche Bank, here's why

Jun 4, 4:34 AM

Abivax price target lowered by $40 at Wolfe Research, here's why

ABVX

Jun 3, 1:18 PM

Abivax rises 13.1%

ABVX

Jun 3, 12:00 PM

Abivax rises 14.1%

ABVX

Jun 3, 10:01 AM

Abivax falls -45.0%

ABVX

Jun 2, 12:00 PM

Abivax falls -40.3%

ABVX

Jun 2, 10:00 AM

Meta Platforms upgraded, Okta downgraded: Wall Street's top analyst calls

+12

Jun 2, 9:43 AM

Abivax price target lowered by $5 at Truist, here's why

ABVX

Jun 2, 8:01 AM

Abivax price target lowered by $13 at Morgan Stanley, here's why

ABVX

Jun 2, 7:51 AM

Wedbush upgrades Abivax to Neutral, lowers target to $90

ABVX

Jun 2, 7:13 AM

Wedbush gets more bullish on Abivax, upgrades shares

ABVX

Jun 2, 7:04 AM

Abivax price target raised by $56 at Citizens, here's why

ABVX

Jun 2, 5:41 AM

Abivax just downgraded at Jefferies, here's why

ABVX

Jun 2, 5:16 AM

Abivax trading resumes

ABVX

Jun 1, 4:30 PM

Abivax announces ABTECT trial meets primary, secondary endpoints

ABVX

Jun 1, 4:14 PM

Abivax trading halted, news pending

ABVX

Jun 1, 4:01 PM

Abivax put volume heavy and directionally bearish

ABVX

May 12, 10:55 AM

Abivax call volume above normal and directionally bullish

ABVX

Apr 28, 10:45 AM

Abivax price target raised by EUR 32 at Oddo BHF, here's why

ABVX

Apr 9, 5:13 AM

Abivax appoints Michael Nesrallah as chief commercial officer

Apr 1, 4:15 PM

Abivax price target raised by $6 at Barclays, here's why

ABVX

Mar 24, 5:29 AM

Abivax initiated with bullish view at Jefferies, here's why

ABVX

Mar 15, 8:11 PM

What You Missed On Wall Street On Thursday

+30

Mar 12, 4:12 PM

Midday Fly By: Dick's Sporting, Dollar General report quarterly beats

+35

Mar 12, 11:53 AM

Abivax gives up gains after denying report of Astra exclusivity

Mar 12, 10:16 AM

Novel Mechanism of Action (MOA): Abivax's lead drug, obefazimod, utilizes a unique approach by targeting microRNA-124 to regulate inflammation, offering a differentiated therapeutic strategy compared to existing treatments for inflammatory bowel diseases.

Advanced Clinical Development Stage: Obefazimod has successfully completed Phase 3 clinical trials for moderate-to-severe ulcerative colitis (UC) with positive results, positioning it for potential regulatory approval and market entry in the near future.

Significant Unmet Market Need: Ulcerative colitis represents a large and growing market with a substantial portion of patients who do not respond adequately to current therapies, creating a high demand for new, effective, and well-tolerated treatment options.

Clinical Trial Failure Risk: The success of their lead candidate, obefazimod, in ongoing and future clinical trials is critical, and failure to meet primary or secondary endpoints or demonstrate sufficient safety and efficacy would severely impact the company's prospects.

Regulatory Approval Uncertainty Risk: Even if clinical trials are successful, there is no guarantee that regulatory bodies such as the FDA or EMA will grant approval for obefazimod, and delays or outright rejections are potential outcomes.

Intense Competition Risk: The market for inflammatory bowel diseases, particularly ulcerative colitis, is highly competitive with numerous established therapies and other drugs in development, which could limit obefazimod's potential market share and commercial success.